Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco.
“We believe that the high efficacy of viral suppression and the safety data support continuing our study and support the clinical development of what we think is an exciting six-monthly HIV regimen,” Dr Onyema Ogbuagu of Yale University said at a conference media briefing.
Lenacapavir, which is administered by injection every six months, is approved for heavily treatment-experienced people with multidrug-resistant HIV. But it currently does not have equally durable partners to build a complete twice-yearly regimen, so for now it must be used with daily oral antiretrovirals. Broadly neutralising antibodies (bnAbs) have the potential to fill that gap.
People living with HIV normally produce HIV-specific antibodies, but these mostly target parts of the virus that are hidden or highly variable. However, a small proportion of people naturally make bnAbs that target conserved parts of the virus that do not change much. These specialised antibodies are being explored for HIV prevention, treatment and cure research. As with antiretroviral drugs, though, the virus can develop resistance to bnAbs, so they are best used in combination therapy.
Read the full news story at aidsmap.
SEE ALSO:
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.